Alaunos Therapeutics, Inc.

About Alaunos Therapeutics, Inc.

Alaunos is a clinical stage cellular immuno-oncology company focused on treating solid tumors through adoptive TCR-T cell therapy. They aim to strike cancer at its core by engineering cell therapies targeting neoantigens from genomic mutations, using proprietary, rapid, and cost-effective solutions to deliver tumor-specific killer T cells to cancer patients with unmet needs.

Products & Services

TCR-T Cell Therapy:A therapy targeting solid tumors using T cell receptor technology to attack cancer cells.

Sleeping Beauty Technology:A non-viral transposition technology with a favorable safety profile, enabling rapid, flexible, and cost-effective manufacturing.

hunTR Platform:A robust discovery engine for human neoantigen T cell receptors, facilitating the expansion of a TCR library.

Specialties

TCR-T Cell Therapy Neoantigen Targeting Solid Tumor Treatment Cellular Immunotherapy

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2000000 MR: - FA: $2.0 Million FAN: 2000000	D: 2025-06-23 FD: 2025-06-23	-

Registered Direct Offering Latest

2025-06-23

$2.0M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

H

Holger Weis

Chair

R

Robert J. Hofmeister

Director

C

Curtis Hogue

DIRECTOR

J

Jaime Vieser

Manager of Brushwood LLC, Former Managing Partner and Co-Principal of Castle Hill Asset Management LLC

R

Robert Postma

PRINCIPAL AND FOUNDER OF WATERMILL ASSET MANAGEMENT CORPORATION

View 2 more team members with Pro

Unlock Full Team Directory

Recent News